The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

Exclusion Criteria

• •1. Subjects who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
• •2. Self-reported severe food allergies or diet restrictions (vegans, vegetarians, Atkins, Fodmap, etc.) that would prevent consumption of study diets.
• •3. Subjects with extreme obesity (BMI \> 35).
• •4. Subjects who are smokers or have smoked in the past year and/or have smoked or ingested THC/marijuana in the past week, or who are unwilling to comply with a 1-week washout.
• •5. Subjects with any disease affecting or impairing the function of the liver, kidney or heart.
• •6. Subjects with moderate to severe hypertension.
• •7. Subjects with diabetes mellitus, hyperthyroidism, hypothyroidism, cardiovascular disease, glaucoma.
• •8. Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal surgery.
• •9. Subjects with known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory diagnostics concerning these diseases will be performed within the present study. Volunteers who are cured of past HepC infection are eligible to participate with doctor's approval letter).
• •10. Alcohol use on average \> 2 servings/day or \> 14 servings/wk (Serving size: 12oz beer/4oz wine/2oz hard liquor) or self-reported binge drinking.
• •11. Subjects that are on vitamin B supplements or multi-vitamins or who have taken vitamin B supplements or multi-vitamins in the past 30 days, or are not willing to comply with a 30-day washout of vitamin B supplements.
• •12. Subjects with possible folate deficiency.
• •13. Subjects taking any other clinically significant drugs as judged by the investigator.
• •14. Subjects with a condition, disease, or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
• •15. Female subjects undergoing treatment for infertility or hormone replacement therapy (Volunteers using hormonal birth control will not be excluded).
• •16. Subjects who have taken antimalarials in the past 60 days.
• •17. Participating in another research study while participating in this research study.
• •18. Non-English speaking
• •19. Subjects with abnormal laboratory results at screening as judged by the investigator or study physician.